ASCO: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer
University of California, Los Angeles (UCLA), Health SciencesA study led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.